Replimune Group, Inc. (REPL): Price and Financial Metrics
GET POWR RATINGS... FREE!
REPL Stock Price Chart Interactive Chart >
REPL Price/Volume Stats
|Current price||$34.00||52-week high||$54.85|
|Prev. close||$33.09||52-week low||$18.40|
|Day high||$34.03||Avg. volume||365,977|
|50-day MA||$33.60||Dividend yield||N/A|
|200-day MA||$36.13||Market Cap||1.58B|
Replimune Group, Inc. (REPL) Company Bio
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.
REPL Latest News Stream
|Loading, please wait...|
REPL Latest Social Stream
View Full REPL Social Stream
Latest REPL News From Around the Web
Below are the latest news stories about Replimune Group Inc that investors may wish to consider to help them evaluate REPL as an investment opportunity.
Photo by koto_feja/E+ via Getty Images On June 3, Replimune (REPL), a medium-cap ($1.6 billion) biotechnology company developing oncolytic immuno-gene therapies, was hammered by the market after it announced updated interim data from the IGNYTE clinical trial, as well as data from RP2 alone and in combination with Opdivo (nivolumab)...
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1
High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data confirms the signal with RP1 in anti-PD1 failed melanoma, uveal melanoma and in treating patients whose cancer has metastasized to the liver Announces plans to initiate broad Phase 2 development of RP2 and/or RP3 in tumor types that commonly metastasize to the liver Virtual investor event to be held at 8:00 a
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma Dosed first patient with RP1 in the anti-PD1 failed NSCLC lung cancer cohort of the IGNYTE study Data update on lead programs to be provided during virtual investor event on June 3, 2021 Strengthened management team to prepare for potential commercial launch and enable further later stage development Ended fiscal year 2021 with approximately $476 million in Cash; Capitalized into second half of 2024 WOBURN, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic® platfo...
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced the strengthening of its executive team with the appointment of Tanya Lewis to a newly created position of Chief Development Operations Officer effective May 10, 2021. Ms. Lewis previously served on Replimune’s board of directors and resigned on May 7th in order to join the executive team. Ms. Lewis joins from Karyopharm Therapeutics, a publicly traded biopharmaceutical company, where she served as Executive Vice President, Chief Regulatory Strategy and Strategic Operations Officer and was responsible for project management and portfolio review including navigating the approval of XP...
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with Libtayo® (cemiplimab) versus Libtayo for the treatment of cutaneous squamous cell carcinoma (CSCC), and for IGNYTE, its registration-directed single arm clinical trial in combination with Opdivo® (nivolumab) for the treatment of anti-PD1 failed melanoma. CERPASS “Based on the depth and durability of responses and the manageable safety profile we have seen in patients with non-melanoma skin cancers treated with RP1 in combination with Opdivo to date,...
REPL Price Returns